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Nanostructured protein materials are gaining interest in biomedicine because of 
their biocompatibility, easy production and functional versatility. Merging 
structure and function in proteins allows designing protein composites with 
refined functions such as cell or tissue targeting. The basis of protein structure 
and biological activity is the attained spatial conformation, in a process tightly 
surveyed by the cell factory. However, at which extent the cell’s quality control 
determines the architecture and biological performance of functional protein 
materials is a neglected issue. We demonstrate here that the activity at the 
systems level of a tumour-targeted protein-only nanoparticle is dramatically 
affected by key knock-out mutations in the quality control network of the 
producing bacteria, resulting in altered biodistribution patterns upon systemic 
administration. Therefore, since the conformational modulation at the molecular 
level determines the macroscopic biological performance, a tailored tuning of 
protein materials’ activities might be approachable, in a bottom-up fashion, by 
the appropriate genetic adjustment of the cell factory’s folding machinery.   
Since the approval of insulin in 1981, [1] about 400 protein drugs, mainly 
produced in microbial cells, [2] have been authorized for use in humans. Apart 
from plain therapeutic cytokines, hormones, enzymes and antibodies, a plethora
of more elaborated protein structures with different extents of complexity have 
been developed as nanoconjugates for drug delivery [3] including nab-
paclitaxel, [4] denileukin difitox, [5] PEG-ADA [6] and pegaspargase. [7] Recent 
developments in the engineering of protein self-assembling [8] and the 
expanding catalogues of homing peptides [9] offer clues for the design and 
construction of smart protein nanostructures intended as functional substrates 
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in regenerative medicine [10] or as vehicles for the cell-targeted delivery of 
payload imaging agents and drugs. [11] Most of these applications are based 
on specific interactions between peptidic ligands displayed on the material’s 
surface and surface-exposed receptors on the membrane of target cells, as 
aiming to internalization or signalling. Engineered protein materials are 
produced, as recombinant versions, in cell factories, mainly bacteria, [12] thus 
benefiting from the versatility and adaptability of biological fabrication. [13] In 
recombinant bacteria, disaggregation, folding and refolding, are executed by the
quality control system (the chaperone-protease network), to minimize 
aggregation and to promote proper folding of engineered polypeptides. [14] 
How the quality control system does handle conventional soluble proteins is 
rather well stablished. [15] However, the cell’s surveillance of bioactive, complex
protein nanostructures performing specialized functions is a neglected issue, 
while it has a pivotal relevance in the context of emerging protein materials. [12]
We have here analyzed the influence of the bacterial quality control on 
hyerarchical structural features and biological performance of smart protein 
materials of biomedical interest, illustated by a tumor-targeted, self-assembling 
nanoparticle produced by recombinant methods.
For that, we selected T22-GFP-H6, an engineered polypeptide (Figure 1A) that 
binds the cytokine receptor CXCR4 via the tumor-homing peptide T22. [16] This
protein spontaneously self-assembles as nanoparticles of ~15 nm, that as 
observed by FESEM [17] (Figure 1B) organize as regular toroid (ring-shaped) 
materials,. When systemically administered in colorectal cancer mice models, 
these particles escape renal filtration and target primary tumour and metastatic 
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foci, through specific internalization in CXCR4+ cells. [17, 18] Both the amino 
terminal T22 and the carboxy terminal H6 are involved in the interactions 
between building blocks that support nanoparticle formation. [19] Since T22 
folds through two disulphide bonds, the fusion protein has been usually 
produced in Escherichia coli BL21 Origami B (TrxB-, Gor-) to facilitate disulphide
bridge formation in a less reducing environment. [17] 
To evaluate to which extent the protein production/folding machinery might have
an impact on protein self-assembling and thus influence architectonic features 
and function of T22-GFP-H6 nanoparticles, the building block was produced in 
E. coli K-12 strains with knock-outed critical agents critical in different arms of 
the protein quality control. For that, we selected the main negative regulator of 
the whole quality control system and main disaggregase/foldase (the chaperone
DnaK, JGT20 strain), the versatile ATPase ClpA (JGT4 strain) involved in ATP-
dependent processes related with protein management, and the key cytosolic 
protease ClpP (JGT19 strain) that degrades misfolding-prone proteins. [20] As 
expected, recombinant proteins produced in these mutants exhibit altered 
proteolytic stability, solubility, aggregation profile and biological activity [20]. 
T22-GFP-H6 was also synthesized in the parental MC4100 ara-D139 Δ(argF-
lac)U169 rpsL150 relA1 flbB5301 deoC1 ptsF25 rbsR). Origami B was kept as a
reference for its ability to favour disulphide bridge formation. In all these strains, 
proteins were produced intracellularly and further purified from bacterial extracts
by His-tag affinity chromatography. This resulted in the protein eluted into two 
separated peaks (P1 and P2, Supplementary Figure 1 A). Signs of differential 
proteolysis (Supplementary Figure 1 B) and variable protein yields (Figure 1 C) 
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were indicative of distinct protein management among the mutant set. Divergent
patterns were observed when comparing Origami B and the K-12 derivatives, 
probably linked to enhanced disulphide bridge formation in the first case. The 
occurrence of two main peaks during imidazole elution indicated alternative 
conformations of the C-terminal hexahistidine, that affect the performance of 
T22-GFP-H6 in the Ni2+ chromatography (P1 generally showing less affinity by 
the matrix). Conformational variability was also supported by the spectrum of 
specific emission values of GFP fluorescence observed when T22-GFP-H6 
particles were produced in alternative strains with aberrant quality control 
circuits (Figure 1 D).
Interestingly, there were no significant differences in the size (measured by 
DLS) and superficial charge (measured as Zeta potential) of the produced 
materials (Figure 1E, F), although P1 particles were slightly smaller than those 
found in P2 (an average of around 14 nm versus 16 nm). TEM and FESEM 
images confirmed the regular size and the ring-shaped nanoparticle 
organization, but also the slight differences between the material size in P1 and 
P2 fractions (Figure 2A). This indicated a robust self-assembling of building 
blocks, resulting in similar oligomers and oligomer-oligomer interactions 
irrespective of the strain used as factory. Despite the homogeneous geometry, 
the penetrability into CXCR4+ HeLa cells was dramatically influenced by the 
genetic background, showing a wide variability when comparing data between 
bacterial strains. In addition, the uptake of P2 fractions was generally higher 
than that of P1’s in the MC4100 background (Figure 2B). This fact supported 
the occurrence of conformational protein variants mostly represented by P1 and
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P2 subpopulations but also modulated by the performance of the quality control 
in particular strains. While exhibiting similar geometries once assembled, the 
T22-homing peptide and the H6 tail of T22-GFP-H6 might be more available for 
cross-molecular interactions (with CXCR4 and Ni2+ respectively) in P2 than in 
P1 particles. H6, being a purification tag, is also a powerful endosomal escape 
agent [21], and its enhanced display would favour not only protein purification 
but also stability of internalized nanoparticles, as it seems to occur in P2 
materials. 
To identify any relevant physicochemical properties of the material that might 
influence cell penetrability we confronted internalization data (Figure 2B) with 
nanoparticle size and Zeta potential, with no observable dependences (p>0.1 in
both cases). However, when matching internalization and specific fluorescence 
data (representative of conformational status), a neat exponential trend of 
internalization (y) as a function of the specific fluorescence (x) was observed 
Figure 2C (left), corresponding to a constant decreasing uptake rate with 
increasing specific fluorescence following 
Equation 1                            =      
for positive parameters A and B, that are constants characteristic of the 
internalization process. In particular, the parameter B might be interpreted as a 
common molecular basis of cell uptake and capacity to emit fluorescence, 
related to protein conformation. In Figure 2C (right), the linear regression of the 
right-hand side of Eq. (1) is displayed, providing parameter values A=
7
 mg/U and B= , for a correlation coefficient 
r=0.82 and a significance of p= .
In summary, the most fluorescent nanoparticles among the whole set, mainly 
represented by P1, showed highly limited cell penetrability probably linked to a 
moderate exposure of H6 and T22 tails (T22-GFP-H6 produced in Origami B 
strain, being an exception). Contrarily, P2 materials were in general less 
fluorescent but more capable to penetrate target cells. This was linked to higher
affinity of P2 materials by the chromatographic matrix, when comparing with 
P1’s. Interestingly, different bacterial strains produced materials along a 
functional spectrum (covering a wide range of cell internalization potential and 
fluorescence emission; Figure 2C), whose ends might be defined by archetypal
P1 and P2 fractions. This suggested a continuum of variants produced by 
bacterial mutants covering a wide range of cell internalization potential and 
fluorescence emission (Figure 2C). In this regard, some particle variants, 
mostly represented (but not exclusively) by P1, exhibited a specific fluorescence
emission higher than the parental, unassembled protein GFP-H6, that was 
estimated to be 7,584 ± 834 Units/mg under the same recording settings. This 
indicated that the assembling of conformational isoforms of the building block 
might activate the GFP chromophore through particular cross-molecular 
interactions. Such particular architecture would restrict the solvent exposure of 
both end terminal tails. Nanoparticle versions with more exposed tails might be 
instead equally or slightly less fluorescent than the wild type GFP-H6.
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This possibility was explored by modelling T22-GFP-H6 nanoparticles, resulting 
in two models that best fitted microscopic images and size measures (P1 and 
P2 in Figure 2D). P1 was characterized by less exposed terminal tails (Figure 
2D, bottom) and by inter-molecular interactions between the overhanging ligand
T22 and residues H148, M154, V163, V164, I167, S202, T203, E222 (amino 
acid numbering from [22]) of the adjacent GFP barrel (Figure 2E).  These 
residues have been previously reported as involved in the modulation of the 
intensity of the fluorescence emission, [23] supporting the idea that T22 could 
modify their molecular environment, enhancing the fluorescence activity of GFP.
[24, 25] In P2 materials, terminal tails are more available to external interactors 
and the GFP chromophore remains unaffected by internal cross-molecular 
contacts. Interestingly, the diameter of the modelled particles, which was not 
used as a modelling restraint, was 14.1 nm for P1 and 16.7 nm for P2, close to 
the experimental diameters and with a very similar difference (about 3 nm) 
between them. When exploring the set of (differently) cell-internalizing P2 
particles, the suspected variability in the conformation of building blocks even 
within a single peak (Figure 2C) was confirmed by comparing the signal 
intensity at 218 nm on circular dichroism spectrum, where greater beta-sheet 
secondary structure signal is displayed by more compacted conformations 
(Supplementary Figure 1 C). 
Geometry (size and shape) and charge of nanostructured materials 
administered systemically determine cell penetrability, local diffusion and 
biodistribution [26]. Being these parameters essentially homogeneous among 
the set of nanoparticles generated here, the potential of T22-GFP-H6 to bind 
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and internalize CXCR4+ cells in vitro is modulated by subtle conformational 
differences in the building blocks. To asses if the variable uptake in vitro could 
also influence the in vivo performance of the material, the biodistribution of P2 
nanoparticles (those among the whole set, exhibiting efficient cell uptake in 
vitro) was evaluated in CXCR4+ colorectal mouse models upon systemic 
administration. Under the homogeneous geometry of the P2 particle set, any 
altered biodistribution map should be uniquely attributed to fine structural 
variability determined by the bacterial genetic background. No fluorescence was
observed in kidney or lung in any case, indicative of high stability of all particle 
isoforms, which remained assembled and dispersed in vivo (Table 1). The 
analysis of particle accumulation in CXCR4-overexpressing tumour tissue 
indeed revealed, at a first glance, heterogeneous tumour targeting (Figure 3 A).
Such analysis was performed by determining CXCR4 expression in all 
individual tumours (Figure 3B and Supplementary Figure 2 B) and re-
evaluating specific fluorescence emission by the IVIS equipment 
(Supplementary Figure 2D). We confirmed the differences in tumour uptake by 
determining immunohistochemically the amount of protein in the cell cytosol 
(Figure 3C). Accumulation in normal tissues (lacking or expressing low levels of
CXCR4) was undetectable for all nanoparticle versions, except for an 
unexpected uptake in brain (Figure 4 A) restricted to endothelial cells (Figure 4 
B), and exclusively observed in the material fabricated by JGT20 (DnaK-) cells 
(Table 1). In this mutant, disaggregation and proteolysis of recombinant proteins
is severely impaired, what results in a dramatic expansion of the spectrum of 
conformational protein variants and a less constrained targeting of the particles 
in vivo, when compared to reference strains. [20] In this regard, the material 
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produced in this genetic background shows an enhanced ability to reach the 
brain upon systemic administration, as compared to its uptake in tumor cells in 
vivo. This is indicative of an acquired capacity to internalize the CXCR4+ 
microendothelia of the brain parenchyma. Conversely, nanoparticles produced 
in MC4100 show a high capacity to internalize epithelial tumor cells while are 
unable to undergo trancytosis through brain endothelial cells. This suggests 
different mechanisms of nanoparticle uptake in the brain and other organs, most
likely determined by the blood-brain barrier (BBB).  [27] In agreement, 
nanoparticles able to cross the BBB display improved transcytosis capacity in 
brain endothelial cells, while they are sorted differently in epithelial cells. [27, 
28] The acquisition or not of BBB-crossing capacities in protein nanoparticles 
might have then subtle conformational bases, what would be of great relevance 
in the design of neurotropic vehicles and in identifying the rules for differential 
receptor-mediated internalization in epithelial tumor cells and other cell types. 
Numerically, tumour targeting in vivo did not perfectly correlate with CXCR4+ 
cell penetration in vitro, but a trend was indeed observed. The materials 
obtained in the wild type K-12 bacteria were the most efficient in reaching the 
tumoral tissue (Figure 3 A), and those fabricated in absence of DnaK (JGT20) 
performed similarly to the particles produced in Origami B. Finally, the particles 
obtained in ClpP- (JGT19) targeted the tumour only poorly (Figure 3 A). 
Data presented in the present study reveals a bottom-up instructive quality 
control in the biofabrication of smart protein complexes that determines not only
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product properties at molecular level but also the macroscopic performance of 
the material (Figure 3 D, Figure 4). Subtle conformational variations in the 
oligomer, while keeping the whole particulate architecture alter the exposure of 
the overhanging tails, profoundly influencing the behaviour of the material in 
biological interfaces both in vitro and at systems level. For instance, using a 
DnaK-deficient strain for particle production might increase the conformational 
variability of the ligand and therefore, expand the spectrum of specific CXCR4+ 
target organs reached by the material upon delivery. Among other parameters 
that are convenient to be tuned in drug delivery, constricting of relaxing the 
biodistribution of a vehicle among target organs might offer interesting 
therapeutic opportunities for personalized medicine. Therefore, the engineering 
of the factory’s quality control should allow the tuning and improvement of 
complex and specialized materials’ functions in the  targeting  driven by 
structured homing peptides. Solving the causative link between particular 
mutations in the cell and the biological activities of the resulting material would 
permit a rational bottom-up design of material properties. Even assuming that 
this might be an unaffordable task, the empirical and systematic screening of 
the factory’s genetic background regarding product properties would pave the 
way to the dramatic improvement of protein based materials for therapeutic 
applications. 
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Table 1.  Biodistribution of CXCR4-targeted protein nanoparticles upon systemic administration.
1 Fluorescence emitted by tumors and normal organs 5 h after the administration of 500 µg of each nanoparticle, expressed as mean ± se 
of  Radiant efficiency ( x e9; [p/sec/cm2/sr)]/µW/cm2). 
Whole Tumor 1 Tumor sections Liver Kidney Lung Brain  sections
Buffer 0.9 ± 0.15 a, b, c 1.5 ± 0.40 d, e, f, g 1.3 ± 0.11 0.52  ± 0.04 0.63 ± 0.04 1.027 ±0.07 i
Origami B
(OmpT-, Lon,
TrxB-, Gor-)
1.5 ± 0.15 a 4.2 ± 0.75 d, h 1.3 ± 0.08 0.51 ±0.03 0.59 ± 0.05 0.96 ± 0.05 j
MC4100 
(wt) k
2.7 ±1.10 b 6.9 ±1.07 e, h 1.80 ± 0.10 0.61 ± 0.07 0.92 ± 0.08 1.27 ±0.04 k
JGT4 
(ClpA-)
1.29 ± 0.29 3.86 ±1.27 2.00 ± 0.26 0.69 ± 0.03 0.95 ± 0.12 1.25 ± 0.03 l 
JGT19
(ClpP-)
0.91 ± 0.07 3.0 ± 0.10 f 1.96 ± 0.34 0.77 ± 0.03 0.78 ± 0.05 1.32 ±0.02 m
JGT20
(DnaK-)
1.47 ±0.14 c 4.27 ± 1.07 g 1.82 ± 0.06 0.89 ± 0.05 0.89 ±0.08 7.73 ± 1.53 i, j, k, l, m
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a, b, c, d, e, f, g, h, i, j  Statistical significance between groups: a, p= 0.003 b, p=0.024; c, p=0.028; d, p= 0.028; e, p=0.025; f, p=0.025; g, p=0.009; h,
p= 0.041; i, p= 019,  j, p=0.003; k, p=0.025;l, p= 0.014; m, p=0.025.
k Wild type regarding protein quality control.
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Figure 1. Biophysical properties of T22-empowered protein nanoparticles. A) 
Molecular modelling of a T22-GFP-H6 monomer, indicating the overhanging end 
terminal tails in orange (peptide T22) and in blue (hexahistidine), respectively. At the 
bottom, a cartoon summarizes the modular nature of the protein. Lengths of the 
modules are here shown as approximate. B) FESEM image of isolated T22-GFP-H6 
nanoparticles produced in Origami B cells, upon purification from cell extracts. Bar 
indicates 50 nm. C) Amounts of T22-GFP-H6 determined upon chromatographic 
purification from bacterial cell extracts, in each of the observed peaks of elution (peak
1, P1; peak 2, P2). See Supplementary Figure 1A for more details. Protein production
was induced in different strains under homogenous conditions. Specific fluorescence 
emission (D), size (E) and Zeta potential (F) of T22-GFP-H6 nanoparticles purified 
from different E. coli strains. MC4100 was used here as a wild type strain, while their 
isogenic derivatives JGT20 (DnaK-), JGT4 (ClpA-) and JGT19 (ClpP-) are knock-out 
mutants in main quality control functions. E. coli Origami B, that favours disulphide 
bridge formation, was also used as reference. P1 and P2 materials were analysed 
17
  
separately. A summary of the experimental methods is offered in the Supplementary 
Information file.
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Figure 2. Biological performance of T22-empowered protein nanoparticles. A) Toroid-
like organization of T22-GFP-H6 nanoparticles produced in different E. coli strains, 
and eluted as P1 and P2 fractions. Particles are visualized in wide FESEM fields. 
TEM images of individual particles are also depicted in the insets. Bars indicate 50 
nm. Microscopy determination confirmed the slightly smaller size of P1 compared to 
P2 particles (in nm: TEM: 16.76±0.37 vs 16.79±0.38, U=4253.5, p=0.953; FESEM: 
16.69±0.49 versus 17.56±0.41, U=4989.0, p=0.186). B) Internalization of T22-GFP-
H6 nanoparticles in HeLa cells. Intracellular fluorescence was recorded upon harsh 
trypsin treatment to remove externally attached protein, and corrected by specific 
fluorescence of each nanoparticle to estimate the protein amount in mass. C) 
Materials’ internalization (as raw data, left and as logarithm, right) is represented 
versus specific fluorescence of each particle. Both P1 and P2 materials were 
dialyzed against low and high salt buffers, and data were recorded for the full set of 
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samples. The vertical dashed line indicates the specific fluorescence of GFP-H6. D) 
3D surface representations of archetypical P1 and P2 nanoparticles in a top view 
(modelled with HADDOCK), obtained enforcing tail-barrel and tail-tail interactions 
respectively. Each monomer is differently coloured. At the bottom, side view of the 
same models with the T22 peptide coloured in orange and the hexahistidine tail in 
blue. Nanoparticle diameters are 14.1 nm for P1 and 16.7 nm for P2. E) 3D 
representation of the GFP segment of the T22-GFP-H6 monomer. From left to right: i)
Surface-accessible residues located at the GFP-dimer interface are shown in surface
representation; residues common to (ii) are shown in orange. ii) Surface-accessible 
residues with low-penalty desolvation as predicted by EDP analysis are shown in 
surface representation; residues common to (i) are shown in orange. iii) Residues 
from the GFP barrel used to drive the docking with Haddock are shown in surface 
representation; passive residues in blue, active in dark yellow. iv) Backbone coloured
in a gradient from blue to red according to the number of times (from 0 to 56, 
respectively) in which a residue is found in an EDP-predicted binding site; residues 
known to affect the fluorescence of the protein are shown in ball & stick 
representation. For clarity, an expanded version of the model in iv panel is depicted in
the Supplementary Figure 3.
.
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Figure 3. Tumor biodistribution of T22-GFP-H6 nanoparticle variants A) 
Representative pictures and quantitation of ex vivo fluorescence emission in 
sectioned tumors (detected by the IVIS Xenogen fluorimeter). The color scale bar 
identifies the intensity of fluorescence emitted by tumor tissue ranges from absent 
(grey color), low (brown), intermediate (red) or high (yellow color). B) High level of 
CXCR4 expression in tumors (deep brown color), showing no statistically significant 
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differences among groups. Displayed are representative colorectal tumor tissues of 
animals to be administered with the buffer or with materials produced in Origami-B, 
MC4100, JGT4, JGT19 or JGT20 bacterial strains. CXCR4 expression is detected 
immunohistochemically (IHC) using an anti-CXCR4 antibody (400 x magnification). 
C) Representative micrographs of nanoparticle internalization in the tumor cell 
cytosol, as detected by IHC using an antibody against the nanoparticle GFP domain. 
The antibody is coupled to peroxidase, and yields a brown precipitate when the 
target protein is detected), which allows the quantitation of nanoparticle 
internalization in the different groups (1000 x magnification). Preparations for 
immunohistochemistry are stained in brown after reacting with an antibody against 
the target protein and counterstained with hematoxilin, which stains in blue color the 
cell nuclei. The amount of target protein detected ranges from low (pale brown color) 
to high (intense brown color). (e.g. CXCR4 receptor in cell surface or GFP domain of 
the nanoparticle inside the cell cytosol). Notice the correlation between tumor emitted
fluorescence (seen in panel A as range of colors) and the IHC detected nanoparticle 
internalization into the tumor cell cytosol (seen in panel C as range of brown color 
intensity).
22
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Figure 4. Biodistribution of T22-empowered protein nanoparticles in normal brain. A) 
Representative fluorescence recording images and quantitation of ex vivo 
fluorescence (measured using the IVIS fluorimeter) in sectioned brain after the 
administration of buffer or materials produced in Origami B, MC4100, JGT4, JGT19 
or JGT20 bacterial strains. B) Representative micrographs of CXCR4 expression in 
brain microvascular endothelia (upper panel, black arrows), and nanoparticle uptake 
in CXCR4+ endothelia (lower panel, black arrows), 5 h after the administration of 
Buffer or JGT20-produced material, as measured by IHC with an anti-GFP antibody 
(400x magnification). Notice the similar CXCR4 expression in brain endothelia of 
Buffer and JG20 groups and the exclusive nanoparticle accumulation in the 
microvasculature in animals treated with nanoparticles produced in JGT20. 
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Strains, culture conditions and protein purification. We used the E. coli K12 
strain MC4100 ([araD139], (argF-lac)169, λ- relA1, rpsL150, rbsR22, flb5301, deoC1, 
pstF25 StrepR), and its derivatives  JGT4 (ClpA−; clpA::kan StrepR); JGT19 (clpP::cat 
StrepR) and JGT20 (dnak756 thr::Tn10, StrepR, TcR). Also, Escherichia coli Origami B 
(BL21, OmpT-, Lon-, TrxB-, Gor-, StrepR, TetR, Novagen) was used as production 
control. K12 strains were transformed with pTrc99a (ApR, IPTG-inducible while 
Origami B was transformed with pET22b, both encoding the protein T22-GFP-H6. All 
strains were cultured in Luria-Bertani (LB) media. [1] Overnight cultures were 
inoculated in shake flasks containing 500 ml of LB with appropriate antibiotics and  
incubated at 37ºC and 250 rpm, growing up to 0.5 and 0.6 OD550 units. The 
expression of T22GFPH6 gene was induced by the addition of 50 µl IPTG at 1 mM 
and cultures were incubated overnight at 20ºC and 250 rpm. Afterwards, cells were 
harvested by centrifugation (3,280 g, 4ºC, 40 min) and pellets were resuspended in 
25 ml of Wash Buffer pH 8.0 (20 mM Tris-HCl, 500 mM NaCl and 20 mM imidazole), 
containing an EDTA-free protease inhibitor cocktail (Complete EDTA-free Roche 
Diagnostics, Indianapolis, USA). Cells were disrupted by pressuring at 1100 psi in a 
French press (Thermo FA-078A) and proteins were purified by His tag-affinity 
chromatography using 1 mL HiTrap Chelating HP column (GE Healthcare, 
Piscataway, NJ) through an AKTA purifier FPLC (GE Healthcare). Separations were 
made by linear gradient of Tris 20 mM, pH 8.0, 500 mM NaCl, and 500 mM 
imidazole. Fractions collected were dialyzed against NaHCO3 160mM pH 7.4 Buffer. 
Protein amounts were determined by Bradford’s assay [2] and analyzed by sodium 
dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) and anti-GFP 
western blot.
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Fluorescence, size particle and zeta potential.  Fluorescence of purified protein
was measured in a spectrometer Cary Eclipse (Varian, Mulgrave Australia) using 1 ml
cuvettes, at 450 nm of excitation wavelength and 510 nm of emission wavelength.
The volume and size distribution of nanoparticles in buffer NaHCO3, as well as zeta
potential, were measured by dynamic light scattering at 633 nm through a Zetasizer
Nano  ZS  (Malvern  Instruments  Limited,  Malvern,  Worcestershire,  UK)  using
disposable  plastic  cuvettes.  Nanoparticles  samples  were  analyzed  by  triplicate
averaging fifteen single measurements. 
Electron  microscopy.  Nanoparticles  were  analysed  by  transmission  electron
microscopy (TEM) and field emission scanning electron microscopy (FESEM). For
TEM, protein samples were negatively stained with uranyl acetate by conventional
methods  [3] and  observed  in  a  Jeol  1400  microscope  operating  at  80  kV  and
equipped with a CCD Gatan Erlangshen ES1000W camera. For the quantification of
nanoparticles  size,  185  particles  were  measured  using  Gatan  Digital  Micrograph
software. For FESEM, protein samples were directly deposited over silicon wafers,
air dried and observed with an in-lens secondary electron detector through a Zeiss
Merlin  microscope  operating  at  2kV.  For  quantification  of  nanoparticle  size
distribution,  a  total  of  214  nanoparticles  were  analysed  with  ImageJ  software.
Statistical differences of quantitative analyses between P1 and P2 were calculated by
Mann-Whitney tests (U) using SPSS 15.0 software.
Protein internalization in cell culture. Protein internalization was analyzed in sub-
confluent HeLa cell cultures in 12 well-plates (Nunclon™ Delta,  Roskilde, Denmark).
Briefly, medium was removed and cells were washed in PBS. Then 250 µl of 25 nM
T22-GFP-H6 in OptiPro (Gibco, Paisley, UK), supplemented with L-Glutamine, were
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added and incubated for 1 h at 37 ºC to allow cell binding and internalization. After
incubation,  trypsin digestion (1 mg/ ml for  15 min),  was carried out.  Trypsin  was
neutralized by the addition of 2 volumes of regular cell culture medium and samples
were centrifuged at 1200 rpm for 5 min. Finally, pellets were resuspended in 300 µl of
PBS  and  intracellular  green  fluorescence  was  analyzed  by  flow  cytometry  in  a
FACSCanto system (Becton Dickinson, Franklin Lakes, NJ), using a 15 W air-cooled
argon-ion  laser  at  488  nm  excitation  for  GFP.  Typically,  data  were  recorded  in
duplicate from 60,000 cell counts.
Modelling.  The T22GFPH6 monomer  was  modelled  by homology using  Modeler
9v13 [4] and the following templates: the peptide polyphemusin I structure (pdb code
1RKK model 1) [5] for T22 (T22-GFP-H6 residues 2 to 19; 74 % identity);  residues
40 to 49 of the globular domain of  Gallus gallus histone H5 (pdb code 1HST)  [6]
(residues 17 to 26; 80 % identity) and the structure with pdb code 1QYO for GFP [7]
(residues 27 to 262; 98 % identity).  The histidine tail  was modelled by Modeller’s
automodel function (residues 263 to 269). 500 models were generated and sorted by
their DOPE score.  [8] Models with “knots”  [9] were removed and the one with the
best  per-residue  score  was  selected.  20  models  with  best  DOPE  score  were
analysed with the Electrostatic-Desolvation-Profile method, [10] after removal of the
N and C terminal  tails,  to  predict  the  binding  patch  in  the  T22-GFP-GFP barrel.
Residues from the patch with a surface accessible area greater than 40 % were used
as Ambiguous Interaction Restraints (AIR) in HADDOCK. Those in the center of the
patch, which were also more frequently predicted by EDP (Figure 2E), were selected
as active residues while the rest were used as passive.
30
  
To construct the nanoparticle models several runs of HADDOCK were performed,
enforcing C5 symmetry and using different active and passive residues as AIR. Three
different  combinations where used: T22-tail  residues (1 to 25 in the T22-GFP-H6
monomer)  as  actives  and  His-tail  residues  (262  to  269)  as  passives;  only  T22
residues  as  actives;  T22-tail  residues  as  actives  and  EDP-predicted  residues  as
actives and passives as previously explained. Histidines were protonated according
to their pKas and pH 7.4 (same used for microscopy sample preparation) using the
protonate3D [11] function from the MOE package.  [12] All generated models where
clustered as explained in  the HADDOCK tutorial  [13] and visually  inspected with
Rasmol [14], which was also used for measurements. 3D representations shown in
figures have been generated with UCSF Chimera.  [15] Diameters were calculated
using the two barrel alpha-carbons farthest apart in the oligomer structure.
Nanoparticle  biodistribution  in  the  CXCR4+  tumor  model.   CXCR4-
overexpressing  SP5  human  colorectal  cancer  line  was  implanted  to  generate
subcutaneous tumors  in  Swiss  nude mice  (Charles  River,  France),  as  previously
described.  [3] When tumors reached ca. 500 mm3 mice were randomly allocated to
Origami B, MC4100, JGT4, JGT19, JGT20 or buffer-treated groups (N=3-5/group).
The study was approved by the Institutional Animal Ethics Committee (protocol Nº
DAAM: 8339). The experimental mice received a single 500 μg intravenous bolus of
the corresponding nanoparticles in carbonate pH 7.5 buffer,  whereas control  mice
received  only  buffer.  At  5  h  post-administration,  the  fluorescence  emitted  by  the
nanoparticles  accumulated  in  the  whole  and  slice  sectioned  tumor  and  normal
tissues (kidney, lung, and heart, liver and brain) was measured ex vivo using IVIS®
Spectrum equipment (Xenogen Biosciences, USA). The fluorescence signal was then
digitalized, subtracting the autofluorescence, displayed as a pseudocolor overlay and
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expressed as Radiant  efficiency.  Data was corrected by the specific fluorescence
emitted by the different nanoparticles.
Histological and immunohistochemical (IHC) analysis. Tumors were fixed and 
paraffin-embedded, cut into 4 m sections, processed as previously described [3, 16]
and H&E stained for histological analysis by two independent observers. CXCR4 
membrane expression and nanoparticle cell internalization in tumor and normal 
tissues was assessed by IHC using primary anti-CXCR4 (1:300; Abcam, UK) or anti-
GFP (1:100; Santa Cruz Biotechnology, USA), and secondary HRP conjugated 
antibody, followed by chromogenic detection. [3] The percent of CXCR4-expressing 
cells in relation to the total cell number and their staining intensity was cuantified, 
scoring each from 0 to 3 (where 3 is the maximal intensity) and multiplying both 
values to obtain the H-score.
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Supplementary Figure 1.  Protein purification and preliminary characterization. A)
Two  protein  peaks  (P1  &  P2)  were  observed  in  the  separation  of  T22-GFP-H6
produced in different E. coli strains, by affinity chromatography against an imidazole
concentration  gradient.  B)  MS  spectra  of  T22-GF-PH6  eluted  in  P2.  Except  for
Origami  B,  the  materials  from  all  strains  separated  into  two  major  peaks
corresponding to the molecular weight of the full-length T22-GFP-H6 (30.6 KDa) and
to a shorter species (~28.5 KDa). C) Circular Dichroism spectra from 260 nm to 205
nm of T22-GFP-H6 of P2 materials produced in different strains. A peak at 218 nm is
observed corresponding to beta-sheet secondary structure signal.
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Supplementary  Figure  2.   A)  Haematoxylin-eosin  stained  of  SP5 subcutaneous
colorectal  tumors showed a similar architecture and histology among tumors.  B)
Significant  differences  in  specific  fluorescence  among  nanoparticle  variants,  as
measured using the IVIS spectrum equipment. 
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Supplementary Figure 3.  3D representation of the GFP segment of the T22-GFP-
H6 monomer.  Backbone coloured in a gradient from blue to red according to the
number of times (from 0 to 56, respectively) in which a residue is found in an EDP-
predicted binding site. Residues known to affect the fluorescence of the protein are
shown in ball & stick representation.
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Graphical abstract
How the quality control of producing cells determines material’s properties is a 
neglected but critical issue in the fabrication of protein biomaterials, which are unique 
in merging structure and function. The molecular chaperoning of protein’s conformational 
status is revealed here as a potent molecular instructor of the macroscopic properties of self-
assembling, cell-targeted protein nanoparticles, including biodistribution upon in vivo 
administration
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